The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Open accessAbstract
BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdensome factor IX replacement. METHODS: genome copies per kilogram of body weight) to 54 men with hemophilia B (factor IX activity ≤2% of the normal value) regardless of preexisting AAV5 neutralizing antibodies. The primary end point was the annualized bleeding rate, evaluated in a noninferiority analysis comparing the rate during months 7 through 18 after etranacogene dezaparvovec treatment with the rate during the lead-in period. Noninferiority of etranacogene dezaparvovec was defined as an upper limit of the two-sided 95% Wald confidence interval of the annualized bleeding rate ratio that was less than the noninferiority margin of 1.8. Superiority, additional efficacy measures, and safety were also assessed. RESULTS: The annualized bleeding rate decreased from 4.19 (95% confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95% CI, 0.81 to 2.82) during months 7 through 18 after treatment, for a rate ratio of 0.36 (95% Wald CI, 0.20 to 0.64; P<0.001), demonstrating noninferiority and superiority of etranacogene dezaparvovec as compared with factor IX prophylaxis. Factor IX activity had increased from baseline by a least-squares mean of 36.2 percentage points (95% CI, 31.4 to 41.0) at 6 months and 34.3 percentage points (95% CI, 29.5 to 39.1) at 18 months after treatment, and usage of factor IX concentrate decreased by a mean of 248,825 IU per year per participant in the post-treatment period (P<0.001 for all three comparisons). Benefits and safety were observed in participants with predose AAV5 neutralizing antibody titers of less than 700. No treatment-related serious adverse events occurred. CONCLUSIONS: Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile. (Funded by uniQure and CSL Behring; HOPE-B ClinicalTrials.gov number, NCT03569891.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, P. H., Macfarlane, D. J., Lam, T., & Stewart, S. M. (2011) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/1479-5868-8-115 · Cited by 3,370
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
WFH Guidelines for the Management of Hemophilia, 3rd edition
Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M. V., Windyga, J., et al. (2020) · Haemophilia · doi:10.1111/hae.14046 · Cited by 2,033
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Self-citationDefinitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Self-citationAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Self-citationMultiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104205 · Cited by 243
Self-citationLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Self-citationWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
Kruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
Chowdary, P., Shapiro, S., Makris, M., Evans, G., Boyce, S., Talks, K., Dolan, G., Reiss, U., Phillips, M., Riddell, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119913 · Cited by 159
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues
Leebeek, F. W. G., & Miesbach, W. (2021) · Blood · doi:10.1182/blood.2019003777 · Cited by 158
Self-citationHurlbut, G. D., Ziegler, R. J., Nietupski, J. B., Foley, J. W., Woodworth, L. A., Meyers, E., Bercury, S. D., Pande, N., Souza, D. W., Bree, M. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.175 · Cited by 148
von Drygalski, A., Giermasz, A., Castaman, G., Key, N. S., Lattimore, S., Leebeek, F. W. G., Miesbach, W., Recht, M., Long, A., Gut, R., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000811 · Cited by 141
Self-citationNathwani, A. C. (2019) · Hematology · doi:10.1182/hematology.2019000007 · Cited by 140
Majowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126
Practical aspects of extended half-life products for the treatment of haemophilia
Lambert, T., Benson, G. M., Dolan, G., Hermans, C. R. J. R., Jiménez‐Yuste, V., Ljung, R. C. R., Morfini, M., Zupančić‐Šalek, S., & Santagostino, E. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718796429 · Cited by 122
Self-citationThe frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B
Soucie, J. M., Monahan, P. E., Kulkarni, R., Konkle, B. A., & Mazepa, M. A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020552 · Cited by 106
Self-citationHassan, S., Monahan, R. C., Mauser‐Bunschoten, E. P., van Vulpen, L. F. D., Eikenboom, J. C. J., Beckers, E. A. M., Hooimeijer, H. L., Ypma, P. F., Nieuwenhuizen, L., Coppens, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15182 · Cited by 101
Self-citationRayment, R., Chalmers, E. A., Forsyth, K., Gooding, R., Kelly, A. M., Shapiro, S., Talks, K., Tunstall, O., Biss, T. T., & British Society for Haematology (2020) · British Journal of Haematology · doi:10.1111/bjh.16704 · Cited by 94
Majowicz, A., Salas, D., Zabaleta, N., Rodríguez‐García, E., González‐Aseguinolaza, G., Petry, H., & Ferreira, V. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.003 · Cited by 76
The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy
Long, B. R., Sandza, K., Holcomb, J., Crockett, L., Hayes, G. M., Arens, J., Fonck, C., Tsuruda, L. S., Schweighardt, B., O’Neill, C. A., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.006 · Cited by 75
Stanford, S. N., Pink, R., Creagh, D., Clark, A., Lowe, G., Curry, N. S., Pasi, J., Perry, D. J., Fong, S., Hayes, G. M., et al. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12177 · Cited by 49
Spronck, E. A., Liu, Y. P., Lubelski, J., Ehlert, E., Gielen, S., Montenegro-Miranda, P. S., de Haan, M., Nijmeijer, B. A., Ferreira, V., Petry, H., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.005 · Cited by 34
Self-citationBurke, T., Asghar, S., O’Hara, J., Chuang, M., Sawyer, E. K., & Li, N. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02152-1 · Cited by 34
Health care resource utilization and cost burden of hemophilia B in the United States
Buckner, T. W., Bocharova, I., Hagan, K. A., Bensimon, A. G., Yang, H., Wu, E. Q., Sawyer, E. K., & Li, N. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003424 · Cited by 33
Måseide, R. J., Berntorp, E. E., Astermark, J., Olsson, A., Bruzelius, M., Frisk, T., Nummi, V., Lassila, R., Tjønnfjord, G. E., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14114 · Cited by 32
Self-citationLeebeek, F. W. G., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R. E. G., Castaman, G., Seifried, E., Schwäble, J., Bonig, H. B., et al. (2020) · Blood · doi:10.1182/blood-2020-139225 · Cited by 19
Self-citation
Cited by
Weinstein, D. A., Derks, T. G., Rodriguez‐Buritica, D. F., Ahmad, A., Couce, M., Mitchell, J. J., Riba‐Wolman, R., Mount, M., Sallago, J. B., Ross, K. M., et al. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70014 · Cited by 30
Brennan, M. T., Passineau, M. J., Saunders, D., Sroussi, H., Gaudilliere, D., Liu, J., Dubois, N., Fernandez, A., & Zeldin, R. K. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.04.002 · Cited by 1
Metadata
- Authors
- Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O’Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J., Hermans, C. R. J. R., Klamroth, R., Lemons, R., Visweshwar, N., von Drygalski, A., Young, G., Crary, S. E., Escobar, M., Gomez, E., Kruse-Jarres, R., Quon, D. V., Symington, E., Wang, M., Wheeler, A. P., Gut, R., Liu, Y. P., Dolmetsch, R. E., Cooper, D. L., Li, Y., Goldstein, B., & Monahan, P. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-02-23
- Volume
- 388
- Issue
- 8
- Pages
- 706-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4321480301
- Cited by
- 364
- References
- 33
- FWCI
- 64.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.